Search

Displaying results 2731 - 2740 of 6196 in total
  1. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    Concizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy. … [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway.

  2. Drug

    APT20TTMG

    go.drugbank.com/drugs/DB32869
    Experimental

    APT20TTMG is a synthetic DNA that modulates U1 small nuclear ribonucleoprotein misassembly.

  3. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase. … As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  4. Drug

    Aurothioglucose

    go.drugbank.com/drugs/DB09121
    ApprovedWithdrawn

    Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression...

  5. Drug

    Mebendazole

    go.drugbank.com/drugs/DB00643
    ApprovedInvestigationalVet approved

    A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]

  6. Drug

    Mecamylamine

    go.drugbank.com/drugs/DB00657
    ApprovedInvestigational

    Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

  7. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  8. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921]. … Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924].

  9. Drug

    Yohimbine

    go.drugbank.com/drugs/DB01392
    ApprovedInvestigationalVet approvedWithdrawn

    It is also alleged to be an aphrodisiac.

  10. Drug

    MK-0731

    go.drugbank.com/drugs/DB08037
    Investigational

    MK-0731 is a kinesin spindle protein inhibitor and antineoplastic agent.